Topic
Pharmaceuticals
1,003 published works
Spicy IP
Brand Name Extensions by Pharma May Finally Be Receiving Scrutiny?
On July 6, the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), published a notice inviting comments on the use of brand name extensions by Pharma Companies.…
Health Care Law Brief
OIG Seeks Comment on Clinical Trial Participant Remuneration Under the AKS and Beneficiary Inducements CMP
By Jacquelyn R. Daniel, Devin Cohen, Matthew J. Westbrook
On June 24, 2026, the Office of Inspector General (“OIG”) for the U.S. Department of Health and Human Services (“HHS”) published a Request for Information (“RFI”) seeking public input on…
Garrigues | Intellectual Property Blog
Pathways to Extend the Term of Pharmaceutical Patents in Mexico
By Garrigues
A combination of regulatory developments and recent judicial criteria have opened different avenues to adjust the duration of exclusivity periods. In recent years, substantial changes have been made to the…
Rivkin Rounds
OIG Green-Lights Free Testing by Pharmaceutical Manufacturer
The U.S. Department of Health and Human Services’ Office of Inspector General (OIG) recently issued a favorable Advisory Opinion (No. 26-14) to a pharmaceutical manufacturer that is proposing to offer…
Global IP & Technology Law Blog
A simple typo costs a patent its priority date
By Alex Wolcott
In a recent precedential decision by the Federal Circuit, the Court delivered a cautionary reminder that errors or omissions in a provisional patent application can have significant consequences for a…
News Items Archive - Wiggin and Dana LLP
Wiggin and Dana Advises BioArctic AB in research and collaboration agreement with Eli Lilly and Company
Wiggin and Dana recently represented BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) in connection with its research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment…
SmarTrade
USTR Launches Section 301 Investigation into Germany’s Underpayment for Pharmaceutical Products
By Scott E. Diamond**, David M. Schwartz, Samir D. Varma
On June 18, 2026, the Office of the U.S. Trade Representative (USTR) announced that it was launching an investigation of Germany under Section 301 of the Trade Act of 1974.…
Spicy IP
SpicyIP Summer School 2026 Starts Tomorrow!
By SpicyIP
Ecumenical Christian Centre We are extremely excited to announce that the 2026 edition of the SpicyIP Summer School begins tomorrow. The programme will start by taking participants through a deep…
Big Molecule Watch
Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars
By Alice Yoon
On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BA6101 (denosumab; injection 60 mg) and…
China Law Insight
医药化学领域补充试验数据的审查标准——也谈司美格鲁肽化合物专利无效案
By King & Wood
作者：邰红 郭煜 2025年12月31日，最高人民法院对司美格鲁肽化合物专利无效案作出二审判决，最终接受了专利权人提交的涉及司美格鲁肽化合物的补充试验数据，并据此撤销了国家知识产权局此前作出的专利权无效宣告决定。显然，在接受补充实验数据的问题上，最高人民法院采取了更为开放的态度。 阅读更多